Background
Cognitive Impairment, cognitive impairment, dementia, MCI, amnestic MCI, cognitive and functional impairments, COA, cognitive impairement, AD
DISORDER, DISEASE, DISEASE COURSE
Mild cognitive impairement (MCI) is a common disorder in older populations with its prevalence increasing with age, as demonstrated by the findings that an estimated 6.7% of persons age 60–64 and 25% of persons age 80–84 are living with MCI globally [The current view of AD is that the disease process and clinical manifestations are distributed along a continuum of decline, with symptoms reflecting mild cognitive impairment (MCI) occurring between "normal aging" and dementia [Given the array of cognitive and functional impairments observed across the AD continuum, selecting suitable clinical outcome assessment (COA) instruments for measuring the effects of treatments in clinical trials with early symptomatic patients requires careful consideration. As AD patients may have a reduced ability to understand the impact of their disease on daily functioning, even early in the disease course [The Alzheimer's Disease Cooperative Study – Activities of Daily Living Scale for use in Mild Cognitive Impairment (ADCS-ADL-MCI) is a functional evaluation scale with the information provided by an informant/caregiver to describe the performance of patients in several ADLs. This measure is commonly used in clinical trials and clinical practice to measure the functional evolution of patients with MCI [In light of the evidence gaps regarding the measurement properties of the ADCS-ADL-MCI, the present study focused on the assessment of the psychometric properties of this instrument in subjects with amnestic MCI, including item-level analyses, internal consistency reliability, and homogeneity, test–retest reliability, construct validity (convergent and discriminant validity, known-groups validity), and responsiveness/sensitivity to change, using data from a large randomised controlled trial.